On August 5, 2021 Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that bind specifically to the A3 adenosine receptor (A3AR), addressing cancer, liver and inflammatory diseases, reportedy that Yossi Borenstein, Shizim group CEO, was elected as an External Director at the Company’s recent annual general meeting (Press release, Can-Fite BioPharma, AUG 5, 2021, View Source [SID1234585947]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

During the past 35 years, Mr. Yossi Bornstein has played key roles in the Israeli biomed industry. He was the General Manager of Bristol-Myers Squibb (Israel). Mr. Bornstein is the CEO and the founder of Shizim group, a life science holding company. He is the Founder of ShizimXL, International Medical Devices & ShizimVS, Digital Health innovation centers. He is the Chairman of GCP Clinical Studies Ltd., one of the top providers of clinical research services and educational programs in Israel. He served as the Biotechnology Committee Chairman of the United States-Israel Science & Technology Commission (the "USISTC"). Mr. Bornstein is the founder of ILSI – Israel Life Science Industry Organization and Founder of ITTN – Israel Tech Transfer Organization. He is a Co-Founder and director of Microbot Medical (NASDAQ: MBOT) and a Director of XACT Robotics.

"We welcome Yossi Borenstein as an External Director and trust that his skills will be highly valuable for Can-Fite," stated Can-Fite CEO Pnina Fishman.